Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/ refractory indolent lymphoma

Chan Yoon Cheah, Loretta J. Nastoupil, Sattva S. Neelapu, Sheryl G. Forbes, Yasuhiro Oki, Nathan H. Fowler

Research output: Contribution to journal › Letter › peer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/ refractory indolent lymphoma'. Together they form a unique fingerprint.